Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
BAG-1 (Bcl-2-associated athanogene 1) was first identified as an anti-apoptotic bcl-2-binding protein. Later it was found to bind the molecular chaperones Hsp70 and Hsc70 through its carboxy-terminal sequence (termed the Bag domain), resulting in the inhibition of the refolding activity of these chaperones. It is thought that by binding and inhibiting these molecular chaperones, BAG-1is able to modulate the expression level of proteins requiring chaperones to fold correctly. One such group of proteins that are affected is glucocorticoid receptors. Other reports have suggested that the level of BAG-1 expression correlates with the aggressiveness of various cancers. Multiple isoforms of BAG-1 are known to exist.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: BAG family molecular chaperone regulator 1; BAG-1; Bcl-2 associating athanogene-1 protein; Bcl-2-associated athanogene 1; Bcl-2-binding protein; BCL2-associated athanogene; glucocortoid receptor-associated protein RAP46; receptor-associated protein, 46-KD
Gene Aliases: BAG-1; BAG1; HAP; RAP46
UniProt ID: (Human) Q99933
Entrez Gene ID: (Human) 573